Ocugen (NASDAQ:OCGN) Issues Earnings Results

Key Points

• Ocugen reported a quarterly loss of $0.01 per share, narrower than the $0.06 loss analysts expected, while revenue of $1.95 million exceeded the $1.32 million estimate.
• The company completed enrollment in its Phase III OCU400 trial and expects top-line results in Q1 2027. Its other late-stage programs also have upcoming milestones, with management targeting three BLA filings by 2028; these are future catalysts, not proof of clinical success.
• Ocugen ended the quarter with $84.6 million in cash, restricted cash and short-term investments, and expects its runway to extend into 2028. Management said this should fund two of its three late-stage programs through anticipated BLA filings, leaving funding needs for the remaining program a consideration.

Ocugen (NASDAQ:OCGN - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.05, FiscalAI reports. The firm had revenue of $1.95 million for the quarter, compared to analysts' expectations of $1.32 million.

Here are the key takeaways from Ocugen's conference call:

• Ocugen completed enrollment in the 140-patient Phase III OCU400 trial for retinitis pigmentosa and expects top-line results in Q1 2027, followed by a planned BLA submission. Management cited supportive earlier-stage results and trial-power analyses, but these do not establish that the pivotal trial will succeed.
• All three late-stage programs are now in Phase III: OCU410 for geographic atrophy dosed its first patient, with enrollment targeted for 2027 and a BLA targeted for 2028; OCU410ST for Stargardt disease is expected to report top-line data in Q2 2027. The company said it remains on track to file three BLAs by 2028.
• For OCU410ST, an independent data monitoring committee recommended continuing the study without changes after a planned interim review. Management said the review involved a small, variable patient group at month eight, and the company remains blinded while it awaits the full month-12 data; the timing of the readout is expected in Q2 2027.
• Ocugen had $84.6 million in cash, restricted cash, and short-term investments at quarter-end and expects its runway to extend into 2028, enough to fund two of three late-stage programs through anticipated BLA filings. Nine-month operating expenses rose to $57 million from $50.5 million a year earlier, leaving funding needs for the remaining program a consideration.
• Ocugen finalized an exclusive OCU400 license for the Middle East and North Africa, with up to $4 million in upfront and potential initial development payments, up to $255 million in sales milestones, and a 22% royalty on net sales. The company also said OCU400 received provisional approval in the Bahamas and expects full approval by year-end, although patient uptake and resulting revenue were not specified.

Ocugen Stock Up 14.5%

NASDAQ OCGN traded up $0.11 during mid-day trading on Wednesday, reaching $0.85. The stock had a trading volume of 6,878,713 shares, compared to its average volume of 7,168,636. Ocugen has a 1 year low of $0.69 and a 1 year high of $2.73. The stock has a market cap of $289.26 million, a PE ratio of -3.29 and a beta of 2.04. The company has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.42. The company has a debt-to-equity ratio of 4.17, a current ratio of 0.80 and a quick ratio of 0.80.

More Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Management outlined three anticipated Phase III readouts, giving investors several potential clinical catalysts to watch. The update also included a new Middle East licensing deal. Ocugen Q3 2026 earnings call transcript
• Positive Sentiment: Ocugen reported $1.95 million in quarterly revenue, above analyst expectations of $1.32 million. One earnings account also reported a loss of $0.01 per share, narrower than the estimated $0.06 loss. Ocugen Q3 earnings results
• Neutral Sentiment: Another report said Ocugen’s loss was $0.06 per share, in line with consensus, underscoring that coverage differed on the EPS comparison. Revenue nevertheless exceeded estimates. Zacks Q3 earnings report
• Negative Sentiment: The Phase III readouts are future catalysts, not results; the investment case remains dependent on clinical progress and execution of the licensing deal.

Insider Buying and Selling

In other Ocugen news, CEO Shankar Musunuri sold 57,264 shares of Ocugen stock in a transaction on Friday, October 9th. The stock was sold at an average price of $0.95, for a total value of $54,400.80. Following the completion of the sale, the chief executive officer owned 1,030,771 shares of the company's stock, valued at approximately $979,232.45. This trade represents a 5.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,051,982 shares of company stock worth $1,088,801. Company insiders own 3.95% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on OCGN. Weiss Ratings upgraded Ocugen from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded Ocugen from a "hold" rating to a "sell" rating in a report on Saturday, October 24th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Ocugen has a consensus rating of "Moderate Buy" and an average target price of $9.50.

Ocugen Company Profile

Ocugen, Inc NASDAQ: OCGN is a biotechnology company focused on developing gene and cell therapies for blindness diseases and vaccines for infectious diseases. The company's programs are designed to address serious conditions with limited treatment options, including inherited retinal diseases and diseases affecting the central retina.

Ocugen's pipeline includes modifier gene therapy candidates intended to treat multiple retinal disorders with a single therapeutic approach. Its lead programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.